Evolent Health

Digital Health Rivals And Regulatory Hurdles Will Erode Prospects

AnalystLowTarget

Not Invested

Consensus Narrative from 13 Analysts

Published

29 Aug 25

Updated

29 Aug 25

AnalystLowTarget's Fair Value

US$9.56

0.5% overvalued

29 Aug

US$9.61

-69.0%

3.7%

-69.0%

3.7%

Author's Valuation

US$9.6

0.5% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$9.6

0.5% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

12.26%

Healthtech revenue growth rate

4.38%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.74%

Calculation

US$241.36m

Earnings '28

6.18x

PE Ratio '28

US$1.49b

Market Cap '28

US$1.49b

Market Cap '28

118.85m

No. shares '28

US$12.54

Share Price '28

US$12.54 Share Price '28

Discounted to 2025 @ 9.75% p.a.

US$9.49

Fair Value '25